Virax Biolabs Group Limited Ordinary Shares (VRAX) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $0.22
• Market Cap: $2.85M
• EPS: $-1.22
• 52-Week High: $1.84
• 52-Week Low: $0.20

About Virax Biolabs Group Limited Ordinary Shares

Virax Biolabs Group Limited is a London-based biotechnology company dedicated to the prevention, detection, and management of viral diseases through cutting-edge diagnostic test kits and innovative medical technologies, including personal protective equipment (PPE). With a strong focus on immunology and a commitment to improving global healthcare outcomes, Virax is strategically positioned to address pressing public health challenges. The company aims to enhance its market presence while play...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Virax Biolabs Group Limited Ordinary Shares and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does VRAX pay dividends?

Virax Biolabs Group Limited Ordinary Shares (VRAX) does not currently pay a regular dividend.

What is VRAX's market cap?

Virax Biolabs Group Limited Ordinary Shares (VRAX) has a market capitalization of $2.85M with a current stock price of $0.22.